TUESDAY DEADLINE: Talis Biomedical Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – TLIS

SAN DIEGO, March 5, 2022 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers of Talis Biomedical Corporation (NASDAQ: TLIS) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.